JP2006505619A - 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体 - Google Patents

半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体 Download PDF

Info

Publication number
JP2006505619A
JP2006505619A JP2005500984A JP2005500984A JP2006505619A JP 2006505619 A JP2006505619 A JP 2006505619A JP 2005500984 A JP2005500984 A JP 2005500984A JP 2005500984 A JP2005500984 A JP 2005500984A JP 2006505619 A JP2006505619 A JP 2006505619A
Authority
JP
Japan
Prior art keywords
substance
component
aggregate
combination
extended surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005500984A
Other languages
English (en)
Japanese (ja)
Inventor
セブク，グレゴール
ヴィエール，ウルリッヒ
Original Assignee
アイディーイーエー アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/357,618 external-priority patent/US20040105881A1/en
Application filed by アイディーイーエー アーゲー filed Critical アイディーイーエー アーゲー
Publication of JP2006505619A publication Critical patent/JP2006505619A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
JP2005500984A 2002-10-11 2003-10-09 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体 Pending JP2006505619A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41784702P 2002-10-11 2002-10-11
US10/357,618 US20040105881A1 (en) 2002-10-11 2003-02-04 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US10/357,617 US7473432B2 (en) 2002-10-11 2003-02-04 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
PCT/EP2003/011202 WO2004032900A1 (en) 2002-10-11 2003-10-09 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005037992A Division JP4555111B2 (ja) 2002-10-11 2005-02-15 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体
JP2008283199A Division JP2009108070A (ja) 2002-10-11 2008-11-04 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体

Publications (1)

Publication Number Publication Date
JP2006505619A true JP2006505619A (ja) 2006-02-16

Family

ID=32995875

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2005500984A Pending JP2006505619A (ja) 2002-10-11 2003-10-09 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体
JP2005037992A Expired - Fee Related JP4555111B2 (ja) 2002-10-11 2005-02-15 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体
JP2008283199A Pending JP2009108070A (ja) 2002-10-11 2008-11-04 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2005037992A Expired - Fee Related JP4555111B2 (ja) 2002-10-11 2005-02-15 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体
JP2008283199A Pending JP2009108070A (ja) 2002-10-11 2008-11-04 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体

Country Status (21)

Country Link
EP (5) EP1829528A3 (https=)
JP (3) JP2006505619A (https=)
KR (1) KR20050055723A (https=)
CN (1) CN1703199B (https=)
AT (1) ATE381316T1 (https=)
AU (1) AU2003273977B2 (https=)
BR (1) BR0315148A (https=)
CA (1) CA2498938A1 (https=)
DE (1) DE60318227T2 (https=)
DK (1) DK1551370T3 (https=)
EA (1) EA010407B1 (https=)
ES (1) ES2298566T3 (https=)
HR (1) HRPK20050421B3 (https=)
IS (1) IS7776A (https=)
MX (1) MXPA05003744A (https=)
NO (1) NO20052281L (https=)
NZ (1) NZ538571A (https=)
PL (1) PL377202A1 (https=)
PT (1) PT1551370E (https=)
SI (1) SI1551370T1 (https=)
WO (1) WO2004032900A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
JP2010539125A (ja) * 2007-09-13 2010-12-16 ビーエーエスエフ ソシエタス・ヨーロピア 浸透増強剤としてのハイドロフォビンポリペプチドの使用
PL214538B1 (pl) * 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
CN105434353A (zh) * 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
GB2486371A (en) * 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
EP2688554A2 (en) * 2011-03-21 2014-01-29 Gregor Cevc Optimised preparations of highly adaptable aggregates
DE112012001382T5 (de) * 2011-03-21 2013-12-19 Gregor Cevc Arzneimittelfreie Zusammensetzungen und Methoden zur Verminderung von peripheren Entzündungen und Schmerzen
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
JP6375301B2 (ja) * 2012-10-26 2018-08-15 オックスフォード ナノポール テクノロジーズ リミテッド 液滴界面
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
AU2014298426B2 (en) * 2013-07-31 2019-07-18 Sequessome Technology Holdings Limited Vesicles
JP6692748B2 (ja) * 2013-09-26 2020-05-13 ナショナル ユニヴァーシティー オブ シンガポール リゾホスファチジルコリンの足場を利用する組成物及び方法
JP6547625B2 (ja) * 2013-10-25 2019-07-24 凸版印刷株式会社 膜小胞回収デバイス、膜小胞回収方法、及び膜小胞分析方法
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
WO2017087685A1 (en) 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
CA3058782A1 (en) 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102149190B1 (ko) 2018-04-09 2020-08-28 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR102209397B1 (ko) 2020-07-21 2021-01-29 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
WO1992003122A1 (de) * 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE69825495T2 (de) * 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
SI1031347T1 (en) * 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers

Also Published As

Publication number Publication date
CN1703199B (zh) 2010-04-28
MXPA05003744A (es) 2005-09-20
WO2004032900A8 (en) 2005-03-31
JP2005213261A (ja) 2005-08-11
NZ538571A (en) 2007-05-31
JP4555111B2 (ja) 2010-09-29
WO2004032900A1 (en) 2004-04-22
PL377202A1 (pl) 2006-01-23
EP1815846A2 (en) 2007-08-08
EP1815847A3 (en) 2008-11-05
SI1551370T1 (sl) 2008-06-30
EP1829527A3 (en) 2008-11-05
CN1703199A (zh) 2005-11-30
DK1551370T3 (da) 2008-03-03
AU2003273977A1 (en) 2004-05-04
IS7776A (is) 2005-03-30
BR0315148A (pt) 2005-08-16
KR20050055723A (ko) 2005-06-13
EP1551370A1 (en) 2005-07-13
EP1829527A2 (en) 2007-09-05
HRPK20050421B3 (en) 2007-06-30
EP1829528A3 (en) 2008-11-05
NO20052281D0 (no) 2005-05-10
EP1551370B1 (en) 2007-12-19
NO20052281L (no) 2005-07-07
CA2498938A1 (en) 2004-04-22
EP1829528A2 (en) 2007-09-05
ES2298566T3 (es) 2008-05-16
ATE381316T1 (de) 2008-01-15
DE60318227T2 (de) 2008-12-04
EA010407B1 (ru) 2008-08-29
AU2003273977B2 (en) 2007-07-12
PT1551370E (pt) 2008-02-07
EA200500632A1 (ru) 2005-12-29
HRP20050421A2 (en) 2005-12-31
EP1815847A2 (en) 2007-08-08
DE60318227D1 (de) 2008-01-31
HK1079113A1 (en) 2006-03-31
EP1815846A3 (en) 2008-10-22
JP2009108070A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
JP4555111B2 (ja) 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体
ZA200405480B (en) Aggregate with increased deformability comprising at least three amphipats for improved transport through semi permeable barriers and for the non invasive drug application in vivo especially through the skin
JP2008519784A (ja) 皮膚状態の治療における拡張表面凝集体
US20250134811A1 (en) Ultraflexible liposomes in gel formulation
HK1149499A (en) Aggregate with increased deformability, comprising at least three amphipats
HK1104967A (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
HK1104966A (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
HK1110504A (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
HK1110505A (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
HK1079113B (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081208

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090113

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20090731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110125